{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:02:44Z","timestamp":1789707764673,"version":"4.0.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,17]]},"DOI":"10.7759\/cureus.116457","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:06:33Z","timestamp":1789704393000},"source":"Crossref","is-referenced-by-count":0,"title":["Procalcitonin-Guided Antimicrobial Therapy: Current Evidence for Clinical Decision-Making and Practical Limitations"],"prefix":"10.7759","author":[{"given":"Sumayyah","family":"Alshammari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basmah","family":"Alrawaili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roaa","family":"Alshammari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saja","family":"Alruwaili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem","family":"Alruwaili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulaziz","family":"Alzahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alhassan","family":"Alzahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32989-7","article-title":"Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study","volume":"395","author":"Rudd KE","year":"2020","unstructured":"Rudd KE, Johnson SC, Agesa KM, et al.. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet. 2020, 395:200-11. 10.1016\/S0140-6736(19)32989-7","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70318-9","article-title":"Antibiotic resistance-the need for global solutions","volume":"13","author":"Laxminarayan R","year":"2013","unstructured":"Laxminarayan R, Duse A, Wattal C, et al.. Antibiotic resistance-the need for global solutions. Lancet Infect Dis. 2013, 13:1057-98. 10.1016\/S1473-3099(13)70318-9","journal-title":"Lancet Infect Dis"},{"key":"ref3","article-title":"Tackling drug-resistant infections globally: final report and recommendations","author":"O'Neill J","year":"2016","unstructured":"O'Neill J. Tackling drug-resistant infections globally: final report and recommendations. Review on Antimicrobial Resistance. 2016, 1-84.","journal-title":"Review on Antimicrobial Resistance"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021444","article-title":"Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors","volume":"89","author":"Becker KL","year":"2004","unstructured":"Becker KL, Nyl\u00e9n ES, White JC, M\u00fcller B, Snider RH Jr. Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. J Clin Endocrinol Metab. 2004, 89:1512-25. 10.1210\/jc.2002-021444","journal-title":"J Clin Endocrinol Metab"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2022-1072","article-title":"How to best use procalcitonin to diagnose infections and manage antibiotic treatment","volume":"61","author":"Schuetz P","year":"2023","unstructured":"Schuetz P. How to best use procalcitonin to diagnose infections and manage antibiotic treatment. Clin Chem Lab Med. 2023, 61:822-8. 10.1515\/cclm-2022-1072","journal-title":"Clin Chem Lab Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30592-3","article-title":"Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis","volume":"18","author":"Schuetz P","year":"2018","unstructured":"Schuetz P, Wirz Y, Sager R, et al.. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. Lancet Infect Dis. 2018, 18:95-107. 10.1016\/S1473-3099(17)30592-3","journal-title":"Lancet Infect Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)00053-0","article-title":"Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial","volume":"16","author":"de Jong E","year":"2016","unstructured":"de Jong E, van Oers JA, Beishuizen A, et al.. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis. 2016, 16:819-27. 10.1016\/S1473-3099(16)00053-0","journal-title":"Lancet Infect Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3343\/alm.2014.34.4.263","article-title":"Update on procalcitonin measurements","volume":"34","author":"Meisner M","year":"2014","unstructured":"Meisner M. Update on procalcitonin measurements. Ann Lab Med. 2014, 34:263-73. 10.3343\/alm.2014.34.4.263","journal-title":"Ann Lab Med"},{"key":"ref9","article-title":"Procalcitonin","author":"Cleland DA","year":"2023","unstructured":"Cleland DA, Eranki AP. Procalcitonin. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000002953","article-title":"Systematic review and meta-analysis of procalcitonin-guidance versus usual care for antimicrobial management in critically ill patients: focus on subgroups based on antibiotic initiation, cessation, or mixed strategies","volume":"46","author":"Lam SW","year":"2018","unstructured":"Lam SW, Bauer SR, Fowler R, Duggal A. Systematic review and meta-analysis of procalcitonin-guidance versus usual care for antimicrobial management in critically ill patients: focus on subgroups based on antibiotic initiation, cessation, or mixed strategies. Crit Care Med. 2018, 46:684-90. 10.1097\/CCM.0000000000002953","journal-title":"Crit Care Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.1.7089","article-title":"Ubiquitous expression of the calcitonin-I gene in multiple tissues in response to sepsis","volume":"86","author":"M\u00fcller B","year":"2001","unstructured":"M\u00fcller B, White JC, Nyl\u00e9n ES, Snider RH, Becker KL, Habener JF. Ubiquitous expression of the calcitonin-I gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab. 2001, 86:396-404. 10.1210\/jcem.86.1.7089","journal-title":"J Clin Endocrinol Metab"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)90277-n","article-title":"High serum procalcitonin concentrations in patients with sepsis and infection","volume":"341","author":"Assicot M","year":"1993","unstructured":"Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet. 1993, 341:515-8. 10.1016\/0140-6736(93)90277-n","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007498.pub3","article-title":"Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections","volume":"10","author":"Schuetz P","year":"2017","unstructured":"Schuetz P, Wirz Y, Sager R, et al.. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev. 2017, 10:CD007498. 10.1002\/14651858.CD007498.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200512-1922OC","article-title":"Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial","volume":"174","author":"Christ-Crain M","year":"2006","unstructured":"Christ-Crain M, Stolz D, Bingisser R, et al.. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med. 2006, 174:84-93. 10.1164\/rccm.200512-1922OC","journal-title":"Am J Respir Crit Care Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s13613-018-0415-5","article-title":"Adherence to a procalcitonin-guided antibiotic treatment protocol in patients with severe sepsis and septic shock","volume":"8","author":"Hohn A","year":"2018","unstructured":"Hohn A, Balfer N, Heising B, Hertel S, Wiemer JC, Hochreiter M, Schr\u00f6der S. Adherence to a procalcitonin-guided antibiotic treatment protocol in patients with severe sepsis and septic shock. Ann Intensive Care. 2018, 8:68. 10.1186\/s13613-018-0415-5","journal-title":"Ann Intensive Care"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00735-2022","article-title":"ERS\/ESICM\/ESCMID\/ALAT guidelines for the management of severe community-acquired pneumonia","volume":"61","author":"Martin-Loeches I","year":"2023","unstructured":"Martin-Loeches I, Torres A, Nagavci B, et al.. ERS\/ESICM\/ESCMID\/ALAT guidelines for the management of severe community-acquired pneumonia. Eur Respir J. 2023, 61:2200735. 10.1183\/13993003.00735-2022","journal-title":"Eur Respir J"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America","volume":"200","author":"Metlay JP","year":"2019","unstructured":"Metlay JP, Waterer GW, Long AC, et al.. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019, 200:e45-67. 10.1164\/rccm.201908-1581ST","journal-title":"Am J Respir Crit Care Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-021-06506-y","article-title":"Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2021","volume":"47","author":"Evans L","year":"2021","unstructured":"Evans L, Rhodes A, Alhazzani W, et al.. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021, 47:1181-247. 10.1007\/s00134-021-06506-y","journal-title":"Intensive Care Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1754","article-title":"International study of the prevalence and outcomes of infection in intensive care units","volume":"302","author":"Vincent JL","year":"2009","unstructured":"Vincent JL, Rello J, Marshall J, et al.. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009, 302:2323-9. 10.1001\/jama.2009.1754","journal-title":"JAMA"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61879-1","article-title":"Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial","volume":"375","author":"Bouadma L","year":"2010","unstructured":"Bouadma L, Luyt CE, Tubach F, et al.. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet. 2010, 375:463-74. 10.1016\/S0140-6736(09)61879-1","journal-title":"Lancet"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-018-2125-7","article-title":"Effect of procalcitonin-guided antibiotic treatment on clinical outcomes in intensive care unit patients with infection and sepsis patients: a patient-level meta-analysis of randomized trials","volume":"22","author":"Wirz Y","year":"2018","unstructured":"Wirz Y, Meier MA, Bouadma L, et al.. Effect of procalcitonin-guided antibiotic treatment on clinical outcomes in intensive care unit patients with infection and sepsis patients: a patient-level meta-analysis of randomized trials. Crit Care. 2018, 22:191. 10.1186\/s13054-018-2125-7","journal-title":"Crit Care"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2018.12.029","article-title":"Procalcitonin-guided antibiotic discontinuation and mortality in critically ill adults: a systematic review and meta-analysis","volume":"155","author":"Pepper DJ","year":"2019","unstructured":"Pepper DJ, Sun J, Rhee C, Welsh J, Powers JH 3rd, Danner RL, Kadri SS. Procalcitonin-guided antibiotic discontinuation and mortality in critically ill adults: a systematic review and meta-analysis. Chest. 2019, 155:1109-18. 10.1016\/j.chest.2018.12.029","journal-title":"Chest"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-017-4683-6","article-title":"Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016","volume":"43","author":"Rhodes A","year":"2017","unstructured":"Rhodes A, Evans LE, Alhazzani W, et al.. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017, 43:304-77. 10.1007\/s00134-017-4683-6","journal-title":"Intensive Care Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-023-04677-2","article-title":"Procalcitonin-guided antibiotic therapy may shorten length of treatment and may improve survival-a systematic review and meta-analysis","volume":"27","author":"Papp M","year":"2023","unstructured":"Papp M, Kiss N, Baka M, et al.. Procalcitonin-guided antibiotic therapy may shorten length of treatment and may improve survival-a systematic review and meta-analysis. Crit Care. 2023, 27:394. 10.1186\/s13054-023-04677-2","journal-title":"Crit Care"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.26458","article-title":"Biomarker-guided antibiotic duration for hospitalized patients with suspected sepsis: the ADAPT-Sepsis randomized clinical trial","volume":"333","author":"Dark P","year":"2025","unstructured":"Dark P, Hossain A, McAuley DF, et al.. Biomarker-guided antibiotic duration for hospitalized patients with suspected sepsis: the ADAPT-Sepsis randomized clinical trial. JAMA. 2025, 333:682-93. 10.1001\/jama.2024.26458","journal-title":"JAMA"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv252","article-title":"Serum procalcitonin measurement and viral testing to guide antibiotic use for respiratory infections in hospitalized adults: a randomized controlled trial","volume":"212","author":"Branche AR","year":"2015","unstructured":"Branche AR, Walsh EE, Vargas R, et al.. Serum procalcitonin measurement and viral testing to guide antibiotic use for respiratory infections in hospitalized adults: a randomized controlled trial. J Infect Dis. 2015, 212:1692-700. 10.1093\/infdis\/jiv252","journal-title":"J Infect Dis"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(12)70323-7","article-title":"Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis","volume":"13","author":"Wacker C","year":"2013","unstructured":"Wacker C, Prkno A, Brunkhorst FM, Schlattmann P. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis. 2013, 13:426-35. 10.1016\/S1473-3099(12)70323-7","journal-title":"Lancet Infect Dis"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2014.12.026","article-title":"The diagnostic accuracy of procalcitonin for bacteraemia: a systematic review and meta-analysis","volume":"21","author":"Hoeboer SH","year":"2015","unstructured":"Hoeboer SH, van der Geest PJ, Nieboer D, Groeneveld AB. The diagnostic accuracy of procalcitonin for bacteraemia: a systematic review and meta-analysis. Clin Microbiol Infect. 2015, 21:474-81. 10.1016\/j.cmi.2014.12.026","journal-title":"Clin Microbiol Infect"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix317","article-title":"Procalcitonin as a marker of etiology in adults hospitalized with community-acquired pneumonia","volume":"65","author":"Self WH","year":"2017","unstructured":"Self WH, Balk RA, Grijalva CG, et al.. Procalcitonin as a marker of etiology in adults hospitalized with community-acquired pneumonia. Clin Infect Dis. 2017, 65:183-90. 10.1093\/cid\/cix317","journal-title":"Clin Infect Dis"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz545","article-title":"Procalcitonin to distinguish viral from bacterial pneumonia: a systematic review and meta-analysis","volume":"70","author":"Kamat IS","year":"2020","unstructured":"Kamat IS, Ramachandran V, Eswaran H, Guffey D, Musher DM. Procalcitonin to distinguish viral from bacterial pneumonia: a systematic review and meta-analysis. Clin Infect Dis. 2020, 70:538-42. 10.1093\/cid\/ciz545","journal-title":"Clin Infect Dis"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1297","article-title":"Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial","volume":"302","author":"Schuetz P","year":"2009","unstructured":"Schuetz P, Christ-Crain M, Thomann R, et al.. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA. 2009, 302:1059-66. 10.1001\/jama.2009.1297","journal-title":"JAMA"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1086\/421997","article-title":"Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis","volume":"39","author":"Simon L","year":"2004","unstructured":"Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis. 2004, 39:206-17. 10.1086\/421997","journal-title":"Clin Infect Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/531166-procalcitonin-guided-antimicrobial-therapy-current-evidence-for-clinical-decision-making-and-practical-limitations","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:06:35Z","timestamp":1789704395000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/531166-procalcitonin-guided-antimicrobial-therapy-current-evidence-for-clinical-decision-making-and-practical-limitations"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":32,"URL":"https:\/\/doi.org\/10.7759\/cureus.116457","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,17]]}}}